The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Self-citationTopp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914
Cited by
Sorted by citations
Items 801–900 of 1,004
Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health
Banerjee, R. K., Shah, N. D., & Dicker, A. P. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.21.00023 · Cited by 38
Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Zhu, C., Wu, Q., Sheng, T., Shi, J., Shen, X., Yu, J., Du, Y., Sun, J., Liang, T., He, K., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.002 · Cited by 39
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
Atilla, P. A., & Atilla, E. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101459 · Cited by 37
Saygin, C., Zhang, P., Stauber, J., Aldoss, I. T., Sperling, A. S., Weeks, L. D., Luskin, M. R., Knepper, T. C., Wanjari, P., Wang, P., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0106 · Cited by 37
Chen, X., Tan, B., Xing, H., Zhao, X., Ping, Y., Zhang, Z., Huang, J., Shi, X., Zhang, N., Lin, B., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03586-1 · Cited by 42
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Frigault, M. J., Graham, C., Berger, T. R., Ritchey, J., Horick, N., El-Jawahri, A. R., Scarfò, I., Schmidts, A., Haradhvala, N. J., Wehrli, M., et al. (2024) · Blood · doi:10.1182/blood.2024024104 · Cited by 37
Membranous nephropathy: pathogenesis and treatments
Wang, M. M., Yang, J., Fang, X., Lin, W., & Yang, Y. (2024) · MedComm · doi:10.1002/mco2.614 · Cited by 40
CAR-T cell combination therapies in hematologic malignancies
Zhou, D., Zhu, X., & Xiao, Y. Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00536-0 · Cited by 39
Molecular landscape and targeted therapy of acute myeloid leukemia
Gu, R., Yang, X. W., & Wei, H. (2018) · Biomarker Research · doi:10.1186/s40364-018-0146-7 · Cited by 37
Jain, T., Sauter, C. S., Shah, G. L., Maloy, M., Chan, J. E., Scordo, M., Avecilla, S. T., Batlevi, Y., Dahi, P. B., Batlevi, C. L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0476-y · Cited by 37
Self-citationExcessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
Wijewarnasuriya, D., Bebernitz, C., Lopez, A. V., Rafiq, S., & Brentjens, R. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0908 · Cited by 38
Self-citationToward “off‐the‐shelf” allogeneic CAR T cells
Aftab, B. T., Sasu, B. J., Krishnamurthy, J., Gschweng, E. H., Alcazer, V., & Depil, S. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.86 · Cited by 40
Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective
Sievers, S., Watson, G., Johncy, S., & Adkins, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00885 · Cited by 39
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
Feucht, J., & Sadelain, M. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.09.001 · Cited by 42
Self-citationA comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy
Cai, C., Tang, D., Han, Y., Shen, E., Abdihamid, O., Guo, C., Shen, H., & Zeng, S. (2020) · Aging · doi:10.18632/aging.104058 · Cited by 38
Jiang, H., Hu, Y., & Mei, H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00247-8 · Cited by 38
Hamilton, J. A. G., Lee, M., Hunter, R., Ank, R. S., Story, J. Y., Talekar, G. R., Sisroe, T., Ballak, D. B., Fedanov, A., Porter, C. C., et al. (2021) · Aging Cell · doi:10.1111/acel.13309 · Cited by 37
Shi, H., Li, K., Ni, Y., Liang, X., & Zhao, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707198 · Cited by 39
Du, J., & Zhang, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03198-7 · Cited by 37
Palomba, M. L., Qualls, D. A., Monette, S., Sethi, S., Doǧan, A., Roshal, M., Sénéchal, B., Wang, X., Rivière, I., Sadelain, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004128 · Cited by 37
Self-citationShort and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage
Alessi, I., Caroleo, A. M., Palma, L. D., Mastronuzzi, A., Stefano, P. R. O., Colafati, G. S., Boni, A., Vecchia, N. D., Velardi, M., Evangelisti, M., et al. (2022) · Cancers · doi:10.3390/cancers14061540 · Cited by 39
Future landscape for the management of membranous nephropathy
Caravaca‐Fontán, F., Yandián, F., & Fervenza, F. C. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad041 · Cited by 37
Song, F., Hu, Y., Zhang, Y., Zhang, M., Yang, T., Wu, W., Huang, S., Xu, H., Chang, A. H., Huang, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005701 · Cited by 38
Liu, S., Zhang, X., Dai, H., Cui, W., Yin, J., Li, Z., Xiao, Y., Yang, C., Xue, S., Qiu, H., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00819-5 · Cited by 37
Self-citationComplexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Smith, R. M., & Shen, R. R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04372-4 · Cited by 40
Simon, B., Harrer, D. C., Schuler‐Thurner, B., Schuler, G., & Uslu, U. (2019) · Cancers · doi:10.3390/cancers11050696 · Cited by 36
How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia
Frisch, A., & Ofran, Y. (2019) · Haematologica · doi:10.3324/haematol.2018.207506 · Cited by 36
Giralt, S., Costa, L. J., Maloney, D. G., Krishnan, A. Y., Fei, M., Antin, J. H., Brunstein, C. G., Geller, N. L., Goodman, S. A., Hari, P., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.018 · Cited by 36
Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors
Wang, Z., Wang, F., Zhong, J., Zhu, T., Zheng, Y., Zhao, T., Xie, Q., Ma, F., Li, R., Tang, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15729-4 · Cited by 37
Fleischer, L. C., Becker, S. A., Ryan, R. E., Fedanov, A., Doering, C. B., & Spencer, H. T. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.003 · Cited by 36
Wei, S., Gu, R., Xu, Y., Liu, X., Xing, Y., Gong, X., Zhou, C., Liu, B., Zhang, G., Liu, K., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0116 · Cited by 36
Self-citationMerker, M., Wagner, J., Kreyenberg, H., Heim, C., Moser, L. M., Wels, W. S., Bonig, H. B., Ivics, Z., Ullrich, E., Klingebiel, T. E., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.581468 · Cited by 36
Wang, Y., Yang, Y., Hong, R., Zhao, H., Wei, G., Wu, W., Xu, H., Cui, J., Zhang, Y., Chang, A. H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00371-6 · Cited by 36
Self-citationCART Cell Toxicities: New Insight into Mechanisms and Management
Zahid, A., Siegler, E. L., & Kenderian, S. S. (2020) · Clinical Hematology International · doi:10.2991/chi.k.201108.001 · Cited by 37
Warda, W., Rocha, M. N. D., Trad, R., Haderbache, R., Salma, Y., Bouquet, L., Roussel, X., Nicod, C., Deschamps, M., & Ferrand, C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00284-3 · Cited by 38
Zhu, F., Wei, G., Liu, Y., Zhou, H., Wu, W., Yang, L., Huang, H., & Hu, Y. (2021) · Cell Transplantation · doi:10.1177/09636897211025503 · Cited by 36
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
Cheng, S., Inghirami, G., Cheng, S., & Tam, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0652-y · Cited by 36
Dhawale, T. M., Johnson, P. C., Gaballa, M., Nelson, A. M., Lavoie, M. W., Boateng, K. Y., Greydanus, C., Frigault, M. J., & El-Jawahri, A. R. (2022) · Cancer · doi:10.1002/cncr.34557 · Cited by 35
Karnik, I., Her, Z., Neo, S. H., Liu, W. N., & Chen, Q. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061600 · Cited by 39
Bachiller, M., Barceló-Genestar, N., Rodríguez-García, A., Alserawan, L., Dobaño‐López, C., Giménez-Alejandre, M., Castellsagué, J., Colell, S., Otero-Mateo, M., Antoñana-Vildosola, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.028 · Cited by 35
Aldoss, I. T., Khaled, S. K., Budde, L. E., & Stein, A. S. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0753-y · Cited by 35
Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice
Wall, D. A., & Krueger, J. (2020) · Current Oncology · doi:10.3747/co.27.5283 · Cited by 36
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
Greil, C., Engelhardt, M. M., Ihorst, G., Duque‐Afonso, J., Shoumariyeh, K., Bertz, H., Marks, R., Zeiser, R., Duyster, J., Finke, J., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01101-z · Cited by 35
Shao, M., Yu, Q., Teng, X., Guo, X., Wei, G., Xu, H., Cui, J., Chang, A. H., Hu, Y., & Huang, H. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01226-9 · Cited by 37
Hu, L., Charwudzi, A., Li, Q., Zhu, W., Tao, Q., Xiong, S., & Zhai, Z. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04451-w · Cited by 36
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
Grover, P., Veilleux, O., Tian, L., Sun, R., Previtera, M. J., Curran, E. K., & Muffly, L. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003482 · Cited by 35
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765097 · Cited by 37
Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?
Gatto, L., Nunno, V. D., Franceschi, E., Tosoni, A., Bartolini, S., & Brandes, A. A. (2022) · Drugs · doi:10.1007/s40265-022-01702-6 · Cited by 35
Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss
Furqan, F., & Shah, N. N. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-024719 · Cited by 35
Metelo, A. M., Jóźwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., Inam, S., Dunlop, A. S., Sanchez, K., Cuthill, K., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0157 · Cited by 35
Mak, J. W. Y., Law, A. W. H., Law, K. W. T., Ho, R., Cheung, C. K. M., & Law, M. F. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i33.4942 · Cited by 34
Sutherland, N. M., Zhou, B., Zhang, L., Ong, M., Hong, J., Pak, A., Liu, K. J., Frigault, M. J., Maus, M. V., Hill, J. A., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.10.021 · Cited by 34
Pierro, J., Saliba, J., Narang, S., Sethia, G., Fleur-Lominy, S. S., Chowdhury, A., Qualls, A., Fay, H., Kilberg, H. L., Moriyama, T., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0092 · Cited by 34
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida, D. V. P., Fong, L. H., Rettig, M. B., & Autio, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278853 · Cited by 34
Meyer, J.-E., Loff, S., Dietrich, J., Spehr, J., Jiménez, G. J., Bonin, M. V., Ehninger, G., Cartellieri, M., & Ehninger, A. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1945804 · Cited by 35
CAR‐Ts: new perspectives in cancer therapy
Abrantes, R., Duarte, H. O., Gomes, C., Wälchli, S., & Reis, C. A. (2022) · FEBS Letters · doi:10.1002/1873-3468.14270 · Cited by 34
Zhang, Y. L., Li, S., Wang, Y., Yang, L., Xu, Y., Rao, Q., Wang, H., Xing, H., Tian, Z., Tang, K., et al. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00270-5 · Cited by 35
Self-citationTaromi, S., Firat, E., Simonis, A., Braun, L. M., Apostolova, P., Elze, M., Passlick, B., Schumacher, A., Lagies, S., Frey, A., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215697 · Cited by 34
To B‐ or not to B‐: A review of lineage switched acute leukemia
Kurzer, J. H., & Weinberg, O. K. (2022) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13923 · Cited by 34
Newman, H. M., Li, Y., Liu, H., Myers, R. M., Tam, V. W., DiNofia, A. M., Wray, L., Rheingold, S. R., Callahan, C. A., White, C., et al. (2022) · Blood · doi:10.1182/blood.2022017866 · Cited by 34
How can Cytokine-induced killer cells overcome CAR-T cell limits
Cappuzzello, E., Vigolo, E., D’Accardio, G., Astori, G., Rosato, A., & Sommaggio, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1229540 · Cited by 34
Hagel, K. R., Arafeh, R., Gang, S., Arnoff, T. E., Larson, R. C., Doench, J. G., Mathewson, N. D., Wucherpfennig, K. W., Maus, M. V., & Hahn, W. C. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2245 · Cited by 34
Hoelzer, D. T., Bassan, R., Boissel, N., Roddie, C., Ribera, J., & Jerkeman, M. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3112 · Cited by 35
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Pfeifer, B. A., Beitelshees, M., Hill, A. B., Bassett, J., & Jones, C. H. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00323-3 · Cited by 33
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D. P., Hosszu, K., Cancio, M., Jakubowski, A. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015157 · Cited by 34
Self-citationCheloni, G., Karagkouni, D., Pita-Juárez, Y. H., Torres, D., Kanata, E., Liegel, J. J., Avigan, Z. M., Saldarriaga, I., Chedid, G., Rallis, K. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59904-x · Cited by 34
Ma, C., Wang, H., Liu, L., Chen, R., Mukherjee, N., Tong, J., Kazmi, S., Fang, X., Witkowski, M. T., Aifantis, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01428-2 · Cited by 35
Lucero, O. M., Parker, K. N., Funk, T., Dunlap, J. B., Press, R. D., Gardner, R., & Chang, B. H. (2019) · British Journal of Haematology · doi:10.1111/bjh.15812 · Cited by 33
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1589374 · Cited by 35
Bouziana, S. D., & Bouzianas, D. G. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.003 · Cited by 33
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
Dwivedi, A., Karulkar, A., Ghosh, S., Srinivasan, S., Kumbhar, B. V., Jaiswal, A. K., Kizhakeyil, A., Asija, S., Rafiq, A., Kumar, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0476 · Cited by 35
Smirnov, S., Petukhov, A., Levchuk, K., Kulemzin, S. V., Staliarova, A., Lepik, K. V., Shuvalov, O. Y., Zaritskey, A. Y., Daks, A. A., & Fedorova, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780145 · Cited by 34
Zhu, X., Hu, H., Xiao, Y., Li, Q., Zhong, Z., Yang, J., Zou, P., Cao, Y., Meng, F., Li, W., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215668 · Cited by 33
Unity brings strength: Combination of CAR-T cell therapy and HSCT
Huang, R., Wang, X., & Zhang, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215721 · Cited by 33
Self-citationPre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7
Bandara, V., Foeng, J., Gundsambuu, B., Norton, T. S., Nápoli, S., McPeake, D. J., Tyllis, T. S., Rad, E. R., Abbott, C. A., Mills, S. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41338-y · Cited by 33
Aujla, A. S., Aujla, R., & Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0160-4 · Cited by 33
Yang, F., Hu, T., Liu, J.-Q., Yu, X., & Ma, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114920 · Cited by 32
Qiu, F., Jiang, P., Zhang, G., An, J., Ruan, K., Lyu, X., Zhou, J., & Sheng, W. (2024) · Nature Communications · doi:10.1038/s41467-024-48607-4 · Cited by 35
Κωστόπουλος, Ν., Costabile, F., Krimitza, E., Beghi, S., Goia, D., Perales-Linares, R. F., Thyphronitis, G., Lariviere, M. J., Chong, E. A., Schuster, S. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012599 · Cited by 34
Gene therapy then and now: A look back at changes in the field over the past 25 years
Wang, D., Stevens, G., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.040 · Cited by 34
Current development of chimeric antigen receptor T-cell therapy
Wang, J., Hu, Y., & Huang, H. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.11.05 · Cited by 33
Bukhari, A. A., Chaer, F. E., Koka, R., Singh, Z. N., Hutnick, E., Ruehle, K., Lee, S., Kocoglu, M. H., Shanholtz, C. B., Badros, A. Z., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25591 · Cited by 32
Bishop, D. C., Caproni, L. J., Gowrishankar, K., Łęgiewicz, M., Karbowniczek, K., Tite, J. P., Gottlieb, D. J., & Micklethwaite, K. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.020 · Cited by 33
Chimeric antigen receptor T‐cell therapy toxicities
Greenbaum, U., Kebriaei, P., Srour, S. A., Olson, A. L., Bashir, Q., Neelapu, S. S., Rezvani, K., & Shpall, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14403 · Cited by 32
The Application of CAR-T Cells in Haematological Malignancies
Skórka, K., Ostapińska, K., Malesa, A., & Giannopoulos, K. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-020-00599-x · Cited by 34
Mo, G., Wang, H., Talleur, A. C., Shahani, S. A., Yates, B., Shalabi, H., Douvas, M. G., Calvo, K. R., Shern, J. F., Chaganti, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001563 · Cited by 32
Mechanisms of response and resistance to CAR T cell therapies
Berger, T. R., & Maus, M. V. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.010 · Cited by 34
Zi, F., Ye, L.-L., Zheng, J. F., Cheng, J., & Wang, Q. M. (2021) · Medicine · doi:10.1097/md.0000000000025786 · Cited by 34
Targeted Therapy in Acute Lymphoblastic Leukaemia
Salvaris, R., & Fedele, P. L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080715 · Cited by 34
Ghosn, M., Cheema, W., Zhu, A., Livschitz, J., Maybody, M., Boas, F. E., Santos, E., Kim, D., Beattie, J. A., Offin, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.003 · Cited by 32
Long non-coding RNAs and microRNAs as crucial regulators in cardio-oncology
Nukala, S. B., Jousma, J., Cho, Y., Lee, W. H., & Ong, S. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00757-y · Cited by 32
Four challenges to CAR T cells breaking the glass ceiling
Bailey, S. R., Berger, T. R., Graham, C., Larson, R. C., & Maus, M. V. (2022) · European Journal of Immunology · doi:10.1002/eji.202250039 · Cited by 34
The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors
DeRenzo, C. C., Krenciute, G., & Gottschalk, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200773 · Cited by 33
Tomás, R. M. F., Martyn, B. T., Bailey, T. L., & Gibson, M. I. (2018) · ACS Macro Letters · doi:10.1021/acsmacrolett.8b00675 · Cited by 32
Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133
Pacheco, J. M., & Bunn, P. A. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.019 · Cited by 32
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31
Ramos, A., Koch, C. E., Liu-Lupo, Y., Hellinger, R. D., Kyung, T., Abbott, K. L., Fröse, J., Goulet, D. R., Gordon, K. S., Eidell, K. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43790-2 · Cited by 32
CAR-T treatment for cancer: prospects and challenges
Chen, R., Chen, L., Wang, C., Zhu, H., Gu, L., Li, Y., Xiong, X., Chen, G., & Jian, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288383 · Cited by 33
Myers, R. M., Devine, K. J., Li, Y., Lawrence, S., Leahy, A. B., Liu, H., Vernau, L. M., Callahan, C. A., Baniewicz, D., Kadauke, S., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012885 · Cited by 31
Ventin, M., Cattaneo, G., Arya, S., Jia, J., Gelmi, M. C., Sun, Y., Maggs, L., Ksander, B. R., Verdijk, R. M., Boland, G. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0071 · Cited by 33
Self-citation
Metadata
- Authors
- Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 449-459
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6637939
- OpenAlex
- W2787621143
- Cited by
- 2,688
- References
- 24
- Citations by year
- 2026: 164 · 2025: 235 · 2024: 306 · 2023: 351 · 2022: 365 · 2021: 403 · 2020: 412 · 2019: 290 · 2018: 156
- FWCI
- 118.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Comprehensive Cancer Network Foundation (Young Investigator Award)
- Emerald Foundation
- National Institute of Health (R01CA138738-05, P01CA059350, P01CA190174-01)
- Leukemia and Lymphoma Society (Career Development Award)
- American Society of Clinical Oncology (Career Development Award)
- Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
- Juno Therapeutics
- Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center
- Stand Up To Cancer
- William Lawrence and Blanche Hughes Foundation
- Annual Terry Fox Run for Cancer Research
- Carson Family Charitable Trust
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 CAR T cells, B-cell acute lymphoblastic leukemia, relapsed leukemia, autologous T cell therapy, cytokine release syndrome, neurotoxicity, disease burden, bone marrow blasts, event-free survival, overall survival, long-term outcomes
- MeSH terms
- Adult, Aged, Follow-Up Studies, Humans, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Survival Analysis, Cytokines, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
